Germany · Delayed Price · Currency is EUR Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of EUR 1.59 billion. The enterprise value is 1.38 billion.
| Market Cap | 1.59B |
| Enterprise Value | 1.38B |
Important Dates
The last earnings date was Sunday, November 23, 2025.
| Earnings Date | Nov 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 991.97M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -6.18% |
| Shares Change (QoQ) | -2.46% |
| Owned by Insiders (%) | 49.71% |
| Owned by Institutions (%) | 0.97% |
| Float | 356.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5,669.37 |
| PB Ratio | 7.18 |
| P/TBV Ratio | 7.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -44.76 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -36.98 |
Financial Position
The company has a current ratio of 14.57, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.57 |
| Quick Ratio | 14.52 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -1,922.61 |
Financial Efficiency
Return on equity (ROE) is -12.77% and return on invested capital (ROIC) is -12.96%.
| Return on Equity (ROE) | -12.77% |
| Return on Assets (ROA) | -12.32% |
| Return on Invested Capital (ROIC) | -12.96% |
| Return on Capital Employed (ROCE) | -22.50% |
| Revenue Per Employee | 1,351 |
| Profits Per Employee | -147,759 |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +876.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +876.88% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 72.59 |
| Average Volume (20 Days) | 30 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of EUR 280,989 and -30.73 million in losses. Loss per share was -0.03.
| Revenue | 280,989 |
| Gross Profit | 101,745 |
| Operating Income | -50.05M |
| Pretax Income | -30.73M |
| Net Income | -30.73M |
| EBITDA | -48.52M |
| EBIT | -50.05M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 214.06 million in cash and 507,182 in debt, giving a net cash position of 213.55 million.
| Cash & Cash Equivalents | 214.06M |
| Total Debt | 507,182 |
| Net Cash | 213.55M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 222.01M |
| Book Value Per Share | 0.23 |
| Working Capital | 201.80M |
Cash Flow
In the last 12 months, operating cash flow was -36.98 million and capital expenditures -217,873, giving a free cash flow of -37.20 million.
| Operating Cash Flow | -36.98M |
| Capital Expenditures | -217,873 |
| Free Cash Flow | -37.20M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 36.21% |
| Operating Margin | -17,811.14% |
| Pretax Margin | -10,937.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.18% |
| Shareholder Yield | 6.18% |
| Earnings Yield | -1.93% |
| FCF Yield | -2.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascletis Pharma has an Altman Z-Score of 15.13 and a Piotroski F-Score of 2.
| Altman Z-Score | 15.13 |
| Piotroski F-Score | 2 |